Global Sexually Transmitted Disease (STD ) Diagnosis Market 2022-2028

Global Sexually Transmitted Disease (STD ) Diagnosis Market 2022-2028

Global Sexually Transmitted Disease (STD) diagnostics market is expected to grow at a CAGR of 8.5% during the forecast period. The major factors that are driving the market growth include increasing prevalence of HIV/HPV infected population across the globe, increased rates of unsafe sex and increasing awareness regarding STDs. STDs are infections caused by organisms that transmit from one person to another through sexual activity. More than 30 different parasites, bacteria, and viruses can cause STDs. Bacterial sexually transmitted infections (STIs) include syphilis, chlamydia, and gonorrhea. Viral STIs include genital herpes and HIV/AIDS.

Moreover, various regulatory authorities have recommended sexually active men and women to have STD screening, which further accelerates the demand for STD testing. Under healthcare services, STD screening services are widely covered which is likely to augment the growth of the global STD diagnostics market. Regulatory authorities such as the WHO have outlined strategies for the prevention and control of STDs. Research activities are being carried out to understand the growing prevalence of STDs, which in turn, is creating scope for the development of advanced STD testing devices. The government organizations such as STD Surveillance Network (SSuN), CDC’s (Centres for Disease Control and Prevention) Division of STD Prevention (DSTDP), and Gonococcal Isolate Surveillance Project (GISP) are taking initiatives to provide access to healthcare services, prevention strategies, and educate the local public regarding STDs.

Segment Outlook

The global STD diagnostics market is segmented on the basis of disease type, product, and end-user. Based on disease type, the market is segmented into chlamydia, syphilis, gonorrhea, herpes simplex virus (HSV), human papillomavirus (HPV), human immunodeficiency virus (HIV) and others. Based on the product, the market is bifurcated into the laboratory and Point-of-Care (POC) testing devices. Based on end-user, the market is segmented into hospitals and clinics, diagnostic centers and homecare.

HIV is anticipated to hold a significant share in the market in 2018, owing to the significant prevalence of HIV and significant awareness for the condition. As per WHO, globally, 37.9 million people were living with HIV at the end of 2018. Further, the number of mortalities reported due to HIV in 2018 was 770,000. Due to this significant prevalence of HIV, the government is taking initiatives for HIV testing. For instance, in July 2015, in the US, the National HIV/AIDS Strategy was released that prioritizes widespread HIV testing to decrease the cases of undiagnosed HIV infection. Several federal agencies are involved in the activities to offer more people with testing. These government initiatives to make HIV testing accessible to the people are primarily supporting the growth of HIV testing.

Regional Outlook

Geographically, the global sexually transmitted diseases (STD) diagnostics market is segmented on the basis of four major regions, including North America, Europe, Asia-Pacific, and RoW. Significant R&D for development of novel STD diagnostic tests and increasing government initiatives to rising access of HIV testing is estimated to offer significant opportunity for the market growth in these regions.

Asia-Pacific is Estimated to Witness Lucrative Growth During the Forecast Period

Asia-pacific is expected to exhibit significant growth during the forecast period. The common STDs reported in China and India includes gonorrhea, syphilis, and HIV/AIDS. In 2016, China implemented sex education classes for middle and high school students to fight the rise in new HIV infections among young people. The classes involve information about HIV prevention and HIV testing alongside issues of sexual responsibility. China took the active-testing approach, in which high-risk groups such as pregnant women, and people who inject drugs are invited to take free HIV tests. This approach has been found to be an effective approach for key affected populations. This has resulted in increasing awareness among people for STD testing and thereby fuels the regional growth of the market.

Competitive Landscape

The major players operating in the global STD diagnostics market include Abbott Laboratories, Inc., Bio-Rad Laboratories, Inc., F. Hoffman-La Roche Ltd., bioMerieux SA, Hologic Inc., and Danaher Corp. To increase their competitiveness, these players are adopting strategies, such as mergers and acquisitions, product launches and partnerships and collaborations. For instance, in May 2019, Abbott Laboratories, Inc. received the WHO Prequalification approval for m-PIMA HIV-1/2 VL, which is the first point-of-care viral load diagnostic test of the globe. The test received CE Mark in December 2018.